CLPT Stock Earnings ClearPoint Neuro Beats EPS, Beats Revenue for Q2 2024
| CLPT Stock | USD 15.75 0.14 0.88% |
Slightly above 63% of Clearpoint Neuro's investor base is looking to short. The analysis of overall sentiment of trading Clearpoint Neuro stock suggests that many investors are alarmed at this time. Clearpoint Neuro's investing sentiment can be driven by a variety of factors including economic data, Clearpoint Neuro's earnings reports, geopolitical events, and overall market trends.
Clearpoint |
CLPT stock results show that ClearPoint Neuro beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Read at investorplace.com
 |
Clearpoint Neuro Fundamental Analysis
We analyze Clearpoint Neuro's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Clearpoint Neuro using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Clearpoint Neuro based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Working Capital
Working Capital Comparative Analysis
Clearpoint Neuro is currently under evaluation in working capital category among its peers. Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
Clearpoint Neuro Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Clearpoint Neuro stock to make a market-neutral strategy. Peer analysis of Clearpoint Neuro could also be used in its relative valuation, which is a method of valuing Clearpoint Neuro by comparing valuation metrics with similar companies.
Peers
Clearpoint Neuro Related Equities
| NARI | Inari Medical | 30.60 | ||||
| CTSO | Cytosorbents Crp | 10.64 | ||||
| APYX | Apyx Medical | 3.61 | ||||
| NPCE | Neuropace | 3.11 | ||||
| RCEL | Avita Medical | 3.10 | ||||
| INSP | Inspire Medical | 3.01 | ||||
| LUNG | Pulmonx Corp | 2.14 | ||||
| KIDS | Orthopediatrics Corp | 1.80 | ||||
| ELMD | Electromed | 1.76 | ||||
| LIVN | LivaNova PLC | 0.59 | ||||
| SRDX | SurModics | 0.48 | ||||
| INGN | Inogen | 1.14 | ||||
| TMCI | Treace Medical | 1.39 | ||||
| TELA | Tela Bio | 2.41 | ||||
| SGHT | Sight Sciences | 2.58 | ||||
| OM | Outset Medical | 9.29 |
Additional Tools for Clearpoint Stock Analysis
When running Clearpoint Neuro's price analysis, check to measure Clearpoint Neuro's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clearpoint Neuro is operating at the current time. Most of Clearpoint Neuro's value examination focuses on studying past and present price action to predict the probability of Clearpoint Neuro's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clearpoint Neuro's price. Additionally, you may evaluate how the addition of Clearpoint Neuro to your portfolios can decrease your overall portfolio volatility.